Ipca Laboratories Ltd Share Price

Q: What is the share price of Ipca Laboratories Ltd today?

Ipca Laboratories Ltd share price as on 22 Jan 2025 is ₹1557.85

Pharmaceuticals - Indian - Bulk Drugs & Formln Lrg

NSE: IPCALAB Mid Cap ISIN: INE571A01038

As on 22 January 2025 at 15:09 IST

₹1,557.85

+ 12.05

(0.78%)

Sell Buy

About Ipca Laboratories Ltd

Ipca Laboratories Ltd., established in the year 1949 and headquartered in Mumbai, is a prominent Indian pharmaceutical multinational. The company has evolved into a major global player, specializing in the manufacturing and distribution of active pharmaceutical ingredients (APIs) and formulations. Their comprehensive product portfolio encompasses generic drugs, OTC medications, and specialty pharmaceuticals. With a commitment to quality, Ipca Laboratories Ltd. has built a strong reputation in both Indian and international markets. Over its rich journey, the company has demonstrated consistent growth and expansion, cementing its position in the pharmaceutical sector. Read More...

Over 1 Month

-2.52%

Over 6 Months

27.35%

Over 1 Year

42.87%

Over 3 Years

46.56%

Ipca Laboratories Ltd Summary

Close ₹ 1,557.85

Open ₹ 1,546.90

High ₹ 1,560.90

Low ₹ 1,521.05

Volume 1,96,450

Net Turnover (in ₹) ₹ 41,15,88,317.45

52Wk High ₹ 1,755.90

52Wk Low ₹ 1,052

52Wk High / Low

1,052

1,755.90

Ipca Laboratories Ltd Fundamentals

Key Financial Data

Market Cap (in ₹Cr) ₹ 39,217.60

EPS (TTM) 27.50

Book Value (BV) 265.61

Div. Yield 0.26 %

P/E (TTM) 60.24

Price/Book Value 5.81

Delivery % 40.94 %

Face Value 1

Key Ratios

PE Ratio 59.22

PB Ratio 4.95

EV to Sales 5.26

PEG Ratio 12.04

ROA 7.02

ROE 9.81

Debt-Equity 0.21

Net Profit Margin 9.73

Operating Profit Margin 21.08

Ipca Laboratories Ltd Financials

Profit and Loss

Consolidated

Standalone

Yearly

Quarterly

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	7,829.81	6,369.94	5,896.36	5,482.83	4,686.03
Total Expenses	6,879.39	5,624.65	4,760.64	4,093.85	3,939.33
Profit Before Tax	842.67	745.29	1,135.72	1,388.98	738.89
Profit After Tax	529.21	491.93	910.95	1,148.84	603.56
Operating Profit after Depreciation	1,088.69	790.83	1,143.41	1,398.02	763.20

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	4,572.69	2,769.64	2,414.77	2,123.59	2,121.21
Total Non Current Assets	5,562.38	3,437.16	3,176.82	2,631.40	2,404.12
Total Current Assets	5,538.90	5,189.27	4,446.71	3,436.96	2,855.71
TOTAL ASSETS	11,101.28	8,626.43	7,623.53	6,068.36	5,259.83
Total Shareholder's Fund	6,332.19	5,842.02	5,464.84	4,701.65	3,627.48

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	944.65	805.81	856.07	1,090.13	570.35
Net Cash used in Investing Activities	-1,215.29	-725	-850.93	-520.69	-509.34
Net Cash used in Financing Activities	-552.55	507.24	426.78	-305.82	-136.54

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	6,277.75	5,925.81	5,491.22	5,201.40	4,402.51
Total Expenses	5,322.23	5,175.32	4,417.11	3,821.44	3,617.54
Profit Before Tax	822.16	750.49	1,074.11	1,379.96	784.97
Profit After Tax	530.41	505.70	860.37	1,140.77	652.46
Operating Profit after Depreciation	1,076.19	794.41	1,081.35	1,388.10	800.76

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	2,533.17	2,487.37	2,156.87	1,869.75	1,855.39
Total Non Current Assets	5,149.38	3,571.82	3,213.98	2,732.34	2,472.46
Total Current Assets	3,509.89	4,875.15	4,224.46	3,277.79	2,712.11
TOTAL ASSETS	8,659.27	8,446.97	7,438.44	6,010.13	5,184.57
Total Shareholder's Fund	6,348.71	5,877.30	5,475.76	4,752.72	3,677.54

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	830.51	762.29	831.72	1,096.06	561.43
Net Cash used in Investing Activities	-1,355.18	-709.61	-811.85	-559.56	-499.13
Net Cash used in Financing Activities	-464.88	506.38	426.04	-307.38	-138.67

Particulars (in ₹ Cr.)	2024-09	2024-06	2024-03	2023-12	2023-09
Total Revenue	2,354.90	2,092.63	2,033.03	2,052.86	2,033.96
Total Expenses	1,913.42	1,699.91	1,711.13	1,721.98	1,673.40
Profit Before Tax	344.83	290.39	76.60	288.89	225.36
Profit After Tax	245.44	198.98	2.91	222.65	137.44
Operating Profit after Depreciation	467.74	413.33	340.82	353.33	399.11

Particulars (in ₹ Cr.)	2024-09	2024-06	2024-03	2023-12	2023-09
Total Revenue	1,810.94	1,565.86	1,510.62	1,506.83	1,662.66
Total Expenses	1,408.83	1,212.62	1,218.28	1,233.79	1,314.39
Profit Before Tax	339.21	287.89	127.30	200.15	245.13
Profit After Tax	244.12	204.13	64.76	136.94	162.13
Operating Profit after Depreciation	419.11	368.63	307.44	289.93	384.41

Ipca Laboratories Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 1,528.38

S2 1,510.97

S3 1,484.18

Pivot 1,555.17

R1 1,572.58

R2 1,599.37

R3 1,616.78

Moving Average

20 SMA 1,635.10

50 SMA 1,582.35

100 SMA 1,551.52

200 SMA 1,410.07

Ipca Laboratories Ltd Corporate Actions

Dividend

Bonus

Splits

Rights

AGM

EGM

Ipca Laboratories Ltd

₹2/Share

Announcement Date 27 Nov 2024

Record Date 27 Nov 2024

Div Yield 200%

Ipca Laboratories Ltd Peer Comparison

Company	Price	Market Cap (in ₹ Cr)
Ipca Laboratories Ltd	₹1,543.45	₹39,157.98
Sun Pharmaceuticals Industries Ltd	₹1,761.80	₹4,22,714.84
Divis Laboratories Ltd	₹5,818.40	₹1,54,460.24
Cipla Ltd	₹1,427.30	₹1,15,270.75
Dr Reddys Laboratories Ltd	₹1,288.45	₹1,07,511.36
Torrent Pharmaceuticals Ltd	₹3,157.60	₹1,06,862.73

Ipca Laboratories Ltd News

Ipca Laboratories Ltd spurts 0.49%, rises for fifth straight session

Ipca Laboratories Ltd is quoting at Rs 1703.45, up 0.49% on the day as on 12:44 IST on the NSE. The stock is up 53% in last one year as compared to a 9.67% jump in NIFTY and a 35.62% jump in the Nifty Pharma.

01 Jan 2025, 01:00 pm

Ipca Laboratories Ltd soars 1.49%, rises for third straight session

Ipca Laboratories Ltd is quoting at Rs 1656.9, up 1.49% on the day as on 12:49 IST on the NSE. The stock is up 48.02% in last one year as compared to a 9.48% gain in NIFTY and a 37.57% gain in the Nifty Pharma index.

30 Dec 2024, 01:05 pm

Ipca Laboratories to voluntarily close its wholly owned subsidiary in Mexico

04 Dec 2024, 04:57 pm

Ipca Laboratories Ltd up for third straight session

Ipca Laboratories Ltd is quoting at Rs 1591.25, up 1.57% on the day as on 12:49 IST on the NSE. The stock is up 50.01% in last one year as compared to a 20.57% spurt in NIFTY and a 38.57% spurt in the Nifty Pharma index.

19 Nov 2024, 01:05 pm

Board of Ipca Laboratories recommends Interim Dividend

Of Rs.2 per share

14 Nov 2024, 03:29 pm

Ipca Laboratories Ltd Stock Analysis

Annual revenue for Ipca Laboratories Ltd increased by 5.94% to ₹6,277.75 crore in FY 2024 from ₹5,925.81 crore in FY 2023.
Annual Net Profit for Ipca Laboratories Ltd increased by 4.89% to ₹530.41 crore in FY 2024 from ₹505.70 crore in FY 2023.
Promoter Shareholding in Ipca Laboratories Ltd decreased by 3.41% in the most recent quarter, from 46.30% in September 2024 to 44.72% in December 2024.
Ipca Laboratories Ltd delivered a 1-year return of 42.87% compared to the Nifty 50, which provided a return of 8.41% as of the last trading session.
Ipca Laboratories Ltd share price moved up by 0.78% from its previous close of INR ₹1,545.80. The latest Ipca Laboratories Ltd share price is INR ₹1,557.85.
Ipca Laboratories Ltd share price today has been at a low of 1,521.05 and a high of 1,560.90. Over the past 52 weeks, the Ipca Laboratories Ltd share price has seen a low of 1,052 and a high of 1,755.90.

About Ipca Laboratories Ltd

Ipca Laboratories Ltd., established in 1949 and headquartered in Mumbai, is a prominent Indian pharmaceutical multinational. The company has evolved into a major global player, specializing in the manufacturing and distribution of active pharmaceutical ingredients (APIs) and formulations. Their comprehensive product portfolio encompasses generic drugs, OTC medications, and specialty pharmaceuticals.

With a commitment to quality, Ipca has built a strong reputation in both Indian and international markets. Over its rich journey, the company has demonstrated consistent growth and expansion, cementing its position in the pharmaceutical sector.

The promoters of the company include Kaygee Investments Private Limited, with a 21.47% stake. A team of managerial promoters manage the operations of the company. They are -

Premchand Godha
Ajit Kumar Jain
Pranay Godha
Prashant Godha
Manisha Premnath

Ipca Laboratories’ main products include APIs, formulations, and branded generics. The company manufactures over 150 formulations. These include oral liquids, tablets, dry powders, and capsules. These products cater to various therapeutic segments, including pain management, rheumatology, and antimalarials. They also serve the hair care therapy segment.

While Ipca Laboratories may not be the largest in terms of market share or capitalization, it is still highly regarded in the market. The company is known for its innovative solutions and customer-centric approach. The registered office of Ipca Laboratories Ltd. is in Kandivli, Mumbai and the office of the registrar is in Vikhroli, Mumbai.

Ipca Laboratories Ltd. stands out as a major player in the pharmaceutical sector. It has a rich history, a robust product portfolio, and a strong market presence. Its strategic partnerships and efficient management continue to drive the company forward.

Impact of Ipca Laboratories Limited

In India and around the world, Ipca Laboratories Ltd. has had a big influence on the pharmaceutical sector. Since its founding in 1949, the company has expanded greatly. It is currently a well-known brand for creating formulations and active pharmaceutical ingredients (APIs). Rheumatology is one of the therapeutic areas in which it makes contributions. Due to this, the company has been able to play a significant role in enhancing healthcare results.

The manufacture and distribution of premium APIs is one of Ipca Laboratories' main contributions. The business produces more than 80 APIs, which are utilized in manufacturing different drugs. Since they make up the active ingredients of medications, these APIs are crucial to the pharmaceutical sector.

Ipca Laboratories has also made a significant impact through its formulation business. The company produces a wide range of generic and branded formulations, including tablets and injectables. These products cater to various therapeutic areas, providing effective treatment options for patients. Ipca’s formulations are known for their efficacy and affordability, making them accessible to a broad population.

The company’s focus on research and development (R&D) has further amplified its impact. Ipca Laboratories invests significantly in R&D to develop new and improved pharmaceutical products. This investment has led to the creation of innovative therapies that address unmet medical needs. For example, Ipca’s advancements in antimalarial drugs have played a crucial role in combating malaria, which affects millions of people worldwide. The company’s R&D efforts keep it at the forefront of pharmaceutical innovation. These efforts continuously contribute to the advancement of medical science.

Ipca Laboratories’ commitment to sustainability and corporate social responsibility (CSR) also highlights its impact. The company engages in various CSR initiatives aimed at improving the quality of life in the communities where it operates. These initiatives include healthcare camps and environmental conservation efforts.

The company’s global reach further underscores its impact. Ipca Laboratories exports its products to over 120 countries, which includes highly regulated markets like the United States and Japan. This extensive global presence ensures that high-quality medications are available to patients worldwide. Ipca’s ability to meet international regulatory standards demonstrates its commitment to quality and safety. This reinforces its reputation as a reliable pharmaceutical manufacturer.

Ipca Laboratories has also played a crucial role in supporting the healthcare infrastructure in India. The company collaborates with various healthcare providers and government agencies. This helps improve access to essential medicines. These collaborations have been especially important during public health emergencies like the COVID-19 pandemic. Ipca’s timely supply of critical medications helped manage the crisis.

The financial performance and growth trajectory of Ipca Laboratories are indicative of its impact on the industry. The company has consistently achieved strong revenue growth. This is driven by its robust product portfolio and strategic market expansion. Ipca’s financial stability provides confidence to investors and stakeholders. It also enables the company to continue investing in innovation and growth.

Ipca Laboratories’ impact is also evident in its role as an employer. The company employs thousands of people, contributing to economic development and social stability. Ipca’s focus on employee development and welfare ensures that its workforce is skilled, motivated, and engaged. This commitment to human capital development is essential for the company’s long-term success and sustainability.